Cipla Ltd. Futures: Live Cipla Ltd. Futures Contract Prices
NiveshIQ
NSE: CIPLA · Pharma
Cipla Ltd.
₹1,366.00▼ ₹7.30 (-0.53%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on CIPLA. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Cipla Ltd.
Cipla Limited is a diversified Indian pharmaceutical company that manufactures and markets generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and specialty formulations across therapeutic areas such as cardiovascular, respiratory, oncology, and infectious diseases. The company’s revenue drivers include its strong presence in the Indian market, expanding international footprint in the United States and South Africa, and a growing biosimilars portfolio. In FY26, Cipla achieved a record revenue of ₹28,000 crore, up from ₹7,119 crore in Q1FY27, reflecting robust sales growth and successful product launches. Recent leadership changes—Sanjeev Kathuria as Oncology Cluster head and Bhushan Malpure as Head of Marketing—signal a strategic focus on oncology and market
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹25,774 Cr +13.30% | ₹27,548 Cr +6.90% | ₹28,163 Cr +2.20% |
| EBITDA Margin | 24.41% | 25.88% | 24.02% |
| Net Profit | ₹4,153 Cr +46.60% | ₹5,269 Cr +26.90% | ₹3,862 Cr -26.70% |
| EPS | ₹51.05 | ₹65.29 | ₹48.03 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Cipla reports record Q1FY27 revenue of ₹7,119 crore
Cipla records highest revenue of ₹28,000 crore in FY26
🔒
+ 3 more stories about Cipla Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹7, 119 Cr, PAT ₹786 Cr, EPS ₹9.77, EBITDA margin 19.7%. Growth context: revenue QoQ +8.8%, PAT QoQ +44.8%. Street verdict: miss, revenue surprise -0.2%, PAT surprise -6.7%.
Management highlights product launches, approvals, therapy‑mix improvement, order wins, deal pipeline and backlog build ...
FY26 (last completed FY): revenue ₹28, 163 Cr, PAT ₹3, 862 Cr, EBITDA margin 24.0%, EPS ₹48.03. Year-on-year: revenue Yo...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for CIPLA
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track CIPLA alongside your other holdings
Unlock full CIPLA research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Cipla Ltd.?
NiveshIQ detects active intelligence signals for Cipla Ltd. (CIPLA) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Cipla Ltd.?
Cipla Ltd. operates in the Pharma sector with a market capitalisation of ₹10,888,909.9L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.